Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600196 Shanghai Fosun Pharmaceutical (Group) Co Ltd SHSE:600196
78 GF Score
Price ¥24.05
GF Value ¥27.05
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Shanghai Fosun Pharmaceutical (Group) Co Valuation Rank Related Terms

SHSE:600196
78GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd SHSE:600196
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of ¥24.05 is trading 11.1% below its estimated GF Value™ of ¥27.05. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for SHSE:600196:

  • Valuation Rank:
  • GF Value™: ¥27.05 vs. price of ¥24.05 (11.1% below fair value)
  • GF Score™: 78/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
78GF Score

Get the complete analysis for SHSE:600196

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.05
Price
¥27.05
GF Value